Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) have been given an average recommendation of “Moderate Buy” by the seven brokerages that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $18.50.

A number of equities research analysts recently issued reports on ATEC shares. Wall Street Zen downgraded shares of Alphatec from a “buy” rating to a “hold” rating in a research note on Friday, September 26th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alphatec in a report on Saturday, September 27th. Barclays reissued an “overweight” rating and set a $22.00 price objective (up from $21.00) on shares of Alphatec in a research note on Monday, August 4th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Alphatec in a research note on Friday, August 1st. Finally, Lake Street Capital upgraded Alphatec to a “buy” rating and set a $18.00 target price for the company in a report on Monday, June 16th.

Alphatec Stock Performance

NASDAQ ATEC opened at $13.96 on Tuesday. The company has a debt-to-equity ratio of 23.22, a current ratio of 2.88 and a quick ratio of 1.77. Alphatec has a 1-year low of $4.88 and a 1-year high of $16.70. The business has a 50 day simple moving average of $15.04 and a two-hundred day simple moving average of $12.55. The stock has a market capitalization of $2.07 billion, a PE ratio of -12.35 and a beta of 1.05.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings data on Thursday, July 31st. The medical technology company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.08. The firm had revenue of $185.54 million for the quarter, compared to analysts’ expectations of $178.85 million. During the same period last year, the company earned ($0.29) earnings per share. The firm’s revenue was up 27.5% on a year-over-year basis. Alphatec has set its FY 2025 guidance at EPS. On average, research analysts predict that Alphatec will post -1.08 EPS for the current fiscal year.

Insiders Place Their Bets

In other Alphatec news, CEO Patrick Miles sold 100,000 shares of the firm’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $13.96, for a total value of $1,396,000.00. Following the completion of the sale, the chief executive officer owned 5,464,078 shares of the company’s stock, valued at $76,278,528.88. This trade represents a 1.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Scott Lish sold 6,323 shares of the business’s stock in a transaction that occurred on Thursday, August 21st. The shares were sold at an average price of $16.01, for a total value of $101,231.23. Following the transaction, the chief operating officer owned 658,707 shares of the company’s stock, valued at $10,545,899.07. This trade represents a 0.95% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 786,057 shares of company stock valued at $11,835,311. 20.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Alphatec

A number of large investors have recently bought and sold shares of ATEC. Ameritas Investment Partners Inc. increased its stake in Alphatec by 8.8% in the second quarter. Ameritas Investment Partners Inc. now owns 11,845 shares of the medical technology company’s stock worth $131,000 after purchasing an additional 955 shares during the period. Nisa Investment Advisors LLC increased its stake in Alphatec by 22.4% in the 2nd quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company’s stock worth $63,000 after buying an additional 1,045 shares during the period. Oppenheimer Asset Management Inc. lifted its holdings in Alphatec by 8.4% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 14,244 shares of the medical technology company’s stock valued at $158,000 after buying an additional 1,100 shares in the last quarter. ProShare Advisors LLC boosted its position in Alphatec by 5.6% in the 2nd quarter. ProShare Advisors LLC now owns 23,790 shares of the medical technology company’s stock valued at $264,000 after buying an additional 1,254 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in Alphatec by 4.6% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 40,734 shares of the medical technology company’s stock valued at $413,000 after buying an additional 1,792 shares during the period. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.